Maine Medicine Weekly Update - Maine Medicine Weekly E-Update, January 18, 2022  (Plain Text Version)

Return to Graphical Version

 

In this issue:
COVID-19 CORNER
•  National Public Health Emergency Extended
•  Johns Hopkins Public Health Podcast: COVID-19 Vaccines and Immunocompromised Patients
•  Research Suggests Nearly $130 Million Spent Annually on Ivermectin Prescriptions
•  U.S. Supreme Court Blocks Employer Vaccine Mandate; Lets Healthcare Mandate Stand
•  US Sets COVID Hospitalization Record
•  NEJM Evidence: A New Digital Journal
FDA NOTICES
•  FDA Warns About Dental Problems with Buprenorphine Dissolved In The Mouth To Treat OUD & Pain
•  FDA Recall: Metformin HCl Extended- Release Tablets USP, 750 mg by Viona Pharmaceuticals
•  Using Data to Improve Opioid Prescribing - new MICIS presentation now available
MAINE LEGISLATURE
•  State Legislature Back in Augusta; MMA Government Affairs Back at It
•  MMA Legislative Committee Meetings
SURVEY REQUEST
•  Maine AAP, Partnership for Children's Oral Health, Count ME In Survey Request
UPCOMING EVENTS
•  Maine AAP: Innovating / Integrating our Way Out of Maine's Oral Health Crisis (Jan 20)
•  AMA Webinar: Implementing the No Surprises Act (Jan 20)
•  Kick-Off Webinar for Implementing the Alliance for Innovation in Maternal Health (AIM) Severe Hypertension in Pregnancy Bundle in Maine - January 26 from 12-1pm
•  Community Health Center Virtual Round Table - February 8th from 12-1PM
•  Upcoming Specialty Society Meetings
HEALTHCARE EMPLOYMENT OPPORTUNITIES
•  Senior Physician Executive (SPE) - Northern Light Health
•  Nurse Practitioner - Nasson Health Care
•  Physician - Nasson Health Care
•  Transformational OB/GYN or Maternal Fetal Medicine Physician leader

 

FDA Warns About Dental Problems with Buprenorphine Dissolved In The Mouth To Treat OUD & Pain

The U.S. Food and Drug Administration (FDA) warns that dental problems have been reported with medicines containing buprenorphine that are dissolved in the mouth.

The U.S. Food and Drug Administration (FDA) warns that dental problems have been reported with medicines containing buprenorphine that are dissolved in the mouth.

The dental problems, including tooth decay, cavities, oral infections, and loss of teeth, can be serious and have been reported even in patients with no history of dental issues.

FDA Announcement (Website)

Downloadable Version (PDF)